The effect of diagnostic criteria on outcome measures in preclinical and prodromal Alzheimer's disease: Implications for trial design

[1]  Philip S. Insel,et al.  Cognitive and functional changes associated with Aβ pathology and the progression to mild cognitive impairment , 2016, Neurobiology of Aging.

[2]  Atsushi Kawaguchi,et al.  Sample Size Estimation for Alzheimer’s Disease Trials from Japanese ADNI Serial Magnetic Resonance Imaging , 2016, Journal of Alzheimer's disease : JAD.

[3]  Michael W. Weiner,et al.  MRI-based brain atrophy rates in ADNI phase 2: acceleration and enrichment considerations for clinical trials , 2015, Neurobiology of Aging.

[4]  Philip S. Insel,et al.  Predicting Reduction of Cerebrospinal Fluid β-Amyloid 42 in Cognitively Healthy Controls. , 2015, JAMA neurology.

[5]  P. Scheltens,et al.  Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer's disease , 2015, Alzheimer's & Dementia.

[6]  W. M. van der Flier,et al.  Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. , 2015, Brain : a journal of neurology.

[7]  Philip S. Insel,et al.  Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease. , 2015, Brain : a journal of neurology.

[8]  Keith A. Johnson,et al.  Synergistic effect of β-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. , 2014, JAMA neurology.

[9]  K. Blennow,et al.  Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography. , 2014, JAMA neurology.

[10]  R. Sperling,et al.  The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. , 2014, JAMA neurology.

[11]  Nick C Fox,et al.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.

[12]  Reisa A. Sperling,et al.  Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer’s Disease , 2014, Science Translational Medicine.

[13]  M. Mintun,et al.  Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β‐amyloid , 2013, Annals of neurology.

[14]  J. Cummings,et al.  Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative , 2013, Neurobiology of Aging.

[15]  A. Dale,et al.  Unbiased comparison of sample size estimates from longitudinal structural measures in ADNI , 2012, Human brain mapping.

[16]  A. Dale,et al.  Enrichment and Stratification for Predementia Alzheimer Disease Clinical Trials , 2012, PloS one.

[17]  A. Dale,et al.  Amyloid-β--associated clinical decline occurs only in the presence of elevated P-tau. , 2012, Archives of neurology.

[18]  M. Sugishita,et al.  [Clinical Dementia Rating (CDR)]. , 2011, Nihon rinsho. Japanese journal of clinical medicine.

[19]  Cindee M. Madison,et al.  Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI , 2011, Neurobiology of Aging.

[20]  Nick C Fox,et al.  The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[21]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[22]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[23]  R. Coleman,et al.  Use of florbetapir-PET for imaging beta-amyloid pathology. , 2011, JAMA.

[24]  Nick C Fox,et al.  Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Aβ1‐42 , 2010, Annals of neurology.

[25]  Nick C Fox,et al.  Reduced sample sizes for atrophy outcomes in Alzheimer's disease trials: baseline adjustment , 2010, Neurobiology of Aging.

[26]  C R Jack,et al.  Serial MRI and CSF biomarkers in normal aging, MCI, and AD , 2010, Neurology.

[27]  Dominic Holland,et al.  Neuroimaging Enrichment Strategy for Secondary Prevention Trials in Alzheimer Disease , 2010, Alzheimer disease and associated disorders.

[28]  Nick C Fox,et al.  Robust atrophy rate measurement in Alzheimer's disease using multi-site serial MRI: Tissue-specific intensity normalization and parameter selection , 2010, NeuroImage.

[29]  M. Weiner,et al.  Relationships between biomarkers in aging and dementia , 2009, Neurology.

[30]  R. Petersen,et al.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.

[31]  A. Dale,et al.  Whole Brain Segmentation Automated Labeling of Neuroanatomical Structures in the Human Brain , 2002, Neuron.

[32]  Nick C. Fox,et al.  The boundary shift integral: an accurate and robust measure of cerebral volume changes from registered repeat MRI , 1997, IEEE Transactions on Medical Imaging.

[33]  J. Yesavage,et al.  Geriatric Depression Scale (GDS): Recent evidence and development of a shorter version. , 1986 .

[34]  M. D. O'Brien,et al.  Cerebral blood flow in dementia , 1986, Neurology.

[35]  K. Davis,et al.  A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.

[36]  S. Folstein,et al.  “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician , 1975 .

[37]  M. Weiner,et al.  This Provisional PDF corresponds to the article as it appeared upon acceptance. Fully formatted PDF and full text (HTML) versions will be made available soon. Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition , 2014 .

[38]  Nick C Fox,et al.  Targeted recruitment using cerebrospinal fluid biomarkers: implications for Alzheimer's disease therapeutic trials. , 2013, Journal of Alzheimer's disease : JAD.

[39]  E. Siemers,et al.  Enriching amnestic mild cognitive impairment populations for clinical trials: optimal combination of biomarkers to predict conversion to dementia. , 2012, Journal of Alzheimer's disease : JAD.

[40]  W. M. van der Flier,et al.  Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease. , 2012, Journal of Alzheimer's disease : JAD.

[41]  S. Edland,et al.  Power calculations for clinical trials in Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.

[42]  P. Visser,et al.  Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design. , 2010, Journal of Alzheimer's disease : JAD.